HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trade Dress Exemption Could Be Short-Term Fix To OTC Label Issues - CTFA

This article was originally published in The Rose Sheet

Executive Summary

A general exemption for OTC products that meet a "clear and conspicuous" performance standard may be an "intermediate fix" for those that do not meet the color requirements in the OTC labeling rule, Cosmetic, Toiletry and Fragrance Association VP-Legal & General Counsel Thomas Donegan said. He spoke at an FDA working group meeting to discuss product labeling in Rockville, Md. Aug. 24.

You may also be interested in...



OTC Labeling Trade Dress Issue Resolved In FDA Technical Amendment

Labeling of over-the-counter drug products may include light type on a dark background providing the combination results in a highly readable contrast, FDA asserts in a technical amendment to the OTC label reform rule published in the Jan. 3 Federal Register.

OTC Labeling Trade Dress Issue Resolved In FDA Technical Amendment

Labeling of over-the-counter drug products may include light type on a dark background providing the combination results in a highly readable contrast, FDA asserts in a technical amendment to the OTC label reform rule published in the Jan. 3 Federal Register.

OTC Label Trade Dress, Multiple Columns Need Quick Resolution - CHPA

The issues of columns and trade dress in the OTC labeling final rule "have lingered too long, and a response from FDA is urgently needed," the Consumer Healthcare Products Association asserts in an Oct. 22 letter to the agency.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel